- Home
- PRLD vs VCRE Comparison
PRLD vs VCRE Comparison
Compare PRLD & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRLD | VCRE |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Sweden |
| Employees | N/A | 40 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.1M | 332.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | VCRE |
|---|---|---|
| Price | $5.58 | $12.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | ★ 368.5K | 2.3K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.83 | $10.50 |
| 52 Week High | $5.91 | $12.85 |
Technical Indicators
Market Signals| Indicator | PRLD | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 33.17 |
| Support Level | $3.92 | $10.50 |
| Resistance Level | $5.62 | $11.59 |
| Average True Range (ATR) | 0.46 | 0.36 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 71.51 | 9.38 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.